Abstract:It remains a big challenge to develop HDAC inhibitors effective for solid tumors. Previous studies have suggested that the feedback activation of JAK-STAT3 pathway represents a key mechanism leading to resistance to HDAC inhibitors in breast cancer, suggesting the therapeutic promise of JAK/HDAC dual inhibitors. In this work, we discovered a series of pyrrolo[2,3-d]pyrimidine-based derivatives as potent JAK and HDAC dual inhibitors. Especially, compounds 15d and 15h potently inhibited JAK1/2/3 and HDAC1/6 and displayed antiproliferative and proapoptotic activities in triple-negative breast cancer cell lines. Besides, compounds 15d and 15h also diminished the activation of LIFR-JAK-STAT signaling triggered by tumor-associated fibroblasts, which suggests that these compounds could potentially overcome the drug resistance caused by the tumor microenvironment. More importantly, compound 15d effectively inhibited the tumor growth in MDA-MB-231 xenograft tumor model. Overall, this work provides valuable leads and novel antitumor mechanisms for the treatment of the SAHA-resistant triple-negative breast cancers.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02111?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02111</a>.Supporting tables; 1H NMR, and 13C NMR of all target compounds; HPLC spectra and HRMS of the representative compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_001.pdf">PDF</a>)Molecular formula stings (CSV) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_002.csv">CSV</a>)Predicted binding mode of 6a in the ATP pocket of JAK2; surface representation of 6a in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_003.pdb">PDB</a>)Predicted binding mode of 15d in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_004.pdb">PDB</a>)Predicted binding mode of 16b in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_005.pdb">PDB</a>)Predicted binding mode of 6a in the active site of HDAC6; surface representation of 6a in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_006.pdb">PDB</a>)Predicted binding mode of 15d in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_007.pdb">PDB</a>)Predicted binding mode of 16b in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_008.pdb">PDB</a>)This article has not yet been cited by other publications.

Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC)

The Design of a Novel Near-Infrared Fluorescent HDAC Inhibitor and Image of Tumor Cells.

Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery

An Activatable and Tumor-Targeting NIR Fluorescent Probe for Imaging of Histone Deacetylase 6 in Cancer Cells and in Vivo

A Reactivity‐Tunable Self‐Immolative Design Enables Histone Deacetylase‐Targeted Imaging and Prodrug Activation

Discovery of non-substrate, environmentally sensitive turn-on fluorescent probes for imaging HDAC8 in tumor cells and tissue slices

Novel Estrogen Receptor Β/histone Deacetylase Dual-Targeted Near-Infrared Fluorescent Probes As Theranostic Agents for Imaging and Treatment of Prostate Cancer.

A NIR Iridium(iii) Complex-Based Luminescence Probe for Imaging Mitochondria Pyruvate Dehydrogenase Kinase 1 in Triple-Negative Breast Cancer Cells

A “Double-Locked” and Enzyme/pH-Activated Theranostic Agent for Accurate Tumor Imaging and Therapy

Recent advances in HDAC-targeted imaging probes for cancer detection

Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer

Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast Cancer

Smart On-Site Immobilizable Near-Infrared II Fluorescent Nanoprobes for Ultra-Long-Term Imaging-Guided Tumor Surgery and Photothermal Therapy

Environment-sensitive Fluorescent Inhibitors of Histone Deacetylase.

Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.

Small molecule HDAC inhibitors: Promising agents for breast cancer treatment

Discovery of Novel Pyrrolo[2,3- d ]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors

pH/Reduction Dual Stimuli-Triggered Self-Assembly of NIR Theranostic Probes for Enhanced Dual-Modal Imaging and Photothermal Therapy of Tumors

Robust ERα-Targeted Near-Infrared Fluorescence Probe for Selective Hydrazine Imaging in Breast Cancer.

A stable NIR fluorescent probe for imaging lipid droplets in triple-negative breast cancer

Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding protein